204 related articles for article (PubMed ID: 19082448)
21. Reg IV: a promising marker of hormone refractory metastatic prostate cancer.
Gu Z; Rubin MA; Yang Y; Deprimo SE; Zhao H; Horvath S; Brooks JD; Loda M; Reiter RE
Clin Cancer Res; 2005 Mar; 11(6):2237-43. PubMed ID: 15788672
[TBL] [Abstract][Full Text] [Related]
22. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma.
Sentani K; Oue N; Tashiro T; Sakamoto N; Nishisaka T; Fukuhara T; Taniyama K; Matsuura H; Arihiro K; Ochiai A; Yasui W
Am J Surg Pathol; 2008 Aug; 32(8):1182-9. PubMed ID: 18580680
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine markers; chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell carcinoma.
Edgren M; Stridsberg M; Kalknar KM; Nilsson S
Anticancer Res; 1996; 16(6B):3871-4. PubMed ID: 9042273
[TBL] [Abstract][Full Text] [Related]
26. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
27. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
28. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
30. Expression of a 65 kDa oncofetal protein in human prostatic carcinoma.
Hanausek M; Walaszek Z; King TM; Amos CI
Oncol Rep; 2003; 10(5):1387-92. PubMed ID: 12883712
[TBL] [Abstract][Full Text] [Related]
31. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma.
Kageyama S; Isono T; Matsuda S; Ushio Y; Satomura S; Terai A; Arai Y; Kawakita M; Okada Y; Yoshiki T
Int J Urol; 2009 May; 16(5):481-6. PubMed ID: 19389084
[TBL] [Abstract][Full Text] [Related]
32. Reg IV expression and clinicopathologic features of gallbladder carcinoma.
Tamura H; Ohtsuka M; Washiro M; Kimura F; Shimizu H; Yoshidome H; Kato A; Seki N; Miyazaki M
Hum Pathol; 2009 Dec; 40(12):1686-92. PubMed ID: 19716164
[TBL] [Abstract][Full Text] [Related]
33. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology.
Gokden N; Kemp SA; Gokden M
Diagn Cytopathol; 2008 Jul; 36(7):473-7. PubMed ID: 18528893
[TBL] [Abstract][Full Text] [Related]
34. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer.
Ishida E; Nakamura M; Shimada K; Tasaki M; Konishi N
Pathobiology; 2009; 76(1):30-8. PubMed ID: 19188748
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine carcinomas of the breast.
Rovera F; Masciocchi P; Coglitore A; La Rosa S; Dionigi G; Marelli M; Boni L; Dionigi R
Int J Surg; 2008; 6 Suppl 1():S113-5. PubMed ID: 19167937
[TBL] [Abstract][Full Text] [Related]
37. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
[TBL] [Abstract][Full Text] [Related]
38. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas.
de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA
Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865
[TBL] [Abstract][Full Text] [Related]
39. Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients.
Kitamura H; Honma I; Torigoe T; Hariu H; Asanuma H; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2007 Jul; 70(1):38-42. PubMed ID: 17656204
[TBL] [Abstract][Full Text] [Related]
40. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
